Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02159950 · ClinicalTrials.gov registry record · Phase 2
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
A Phase 2 study of Metastatic Prostate Carcinoma and Recurrent Prostate Carcinoma, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT02159950 is a Phase 2 study of Metastatic Prostate Carcinoma and Recurrent Prostate Carcinoma that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 2 participants, below the 132-participant average among 37 other Metastatic Prostate Carcinoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02159950, a Phase 2 study of Metastatic Prostate Carcinoma and Recurrent Prostate Carcinoma, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized phase II trial studies how well sipuleucel-T with or without tasquinimod works in treating patients with hormone-resistant prostate cancer that has spread to other parts of the body. Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells. Tasquinimod may stop the growth of prostate cancer by blocking the growth of new blood vessels necessary for tumor growth. It is not yet known whether sipuleucel-T is more effective with or without tasquinimod in treating prostate cancer.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Sipuleucel-T
- DRUG Tasquinimod
Study Locations (1)
New York
- Roswell Park Cancer Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02159950
The ClinicalTrials.gov registry entry for NCT02159950 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 132-participant average among 37 other Metastatic Prostate Carcinoma trials with a reported enrollment target (98% lower). The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Metastatic Prostate Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02159950 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02159950 about?
NCT02159950 is a clinical study titled "Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer". This randomized phase II trial studies how well sipuleucel-T with or without tasquinimod works in treating patients with hormone-resistant prostate cancer that has spread to other parts of the body. Vaccines made from a person's tumor cells and white blood cells may help the body build an effective ...
What is the current status of trial NCT02159950?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2015-01.
What conditions does trial NCT02159950 study?
This clinical trial studies the following conditions: Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer, Hormone-Resistant Prostate Cancer.
What interventions are being tested in trial NCT02159950?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Sipuleucel-T (BIOLOGICAL), Tasquinimod (DRUG).
Who is sponsoring clinical trial NCT02159950?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02159950 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Prostate Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer
RECRUITING · Phase 2
-
Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy
RECRUITING · Phase 2
-
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
RECRUITING · Phase 2
-
Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.